FADROZOLE HYDROCHLORIDE

• CAT Number: I011410
• CAS Number: 102676-31-3
• Molecular Formula: C14H14ClN3
• Molecular Weight: 259.737
• Purity: ≥95%
• Target: Cytochrome P450
• Storage: -20°C
• IUPAC Name: 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile;hydrochloride
• InChI: InChI=1S/C14H13N3.ClH/c15-8-11-4-6-12(7-5-11)14-3-1-2-13-9-16-10-17(13)14;/h4-7,9-10,14H,1-3H2;1H
• InChIKey: UKCVAQGKEOJTSR-UHFFFAOYSA-N
• SMILES: C1CC(N2C=NC=C2C1)C3=CC=C(C=C3)C#N.Cl

Fadrozole hydrochloride (CAT: I011410) is a selective aromatase inhibitor. Aromatase is an enzyme responsible for the conversion of androgens into estrogens, and by inhibiting this enzyme, fadrozole hydrochloride reduces the production of estrogen. It has been primarily studied for its potential use in the treatment of hormone-sensitive breast cancer, as estrogen plays a crucial role in the growth and proliferation of hormone receptor-positive breast cancer cells. Fadrozole hydrochloride is also used in preclinical research to investigate the role of estrogen in various physiological and pathological processes.

Reference

1:Metabolomic, behavioral, and reproductive effects of the aromatase inhibitor fadrozole hydrochloride on the unionid mussel Lampsilis fasciola. Leonard JA, Cope WG, Barnhart MC, Bringolf RB.Gen Comp Endocrinol. 2014 Sep 15;206:213-26. doi: 10.1016/j.ygcen.2014.07.019. Epub 2014 Jul 27. PMID: 25072892
2:The effects of the aromatase inhibitor fadrozole hydrochloride on fetuses and uteri in late pregnant rats. Tamada H, Shimizu Y, Inaba T, Kawate N, Sawada T.J Endocrinol. 2004 Feb;180(2):337-45. PMID: 14765986 Free Article
3:Delayed implantation induced by fadrozole hydrochloride in rats. Tamada H, Mizuta Y, Kawate N, Inaba T, Sawada T.Contraception. 2003 Jul;68(1):65-8. PMID: 12878290
4:Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 4). Fadrozole hydrochloride: an oral 2/4-week male reproductive organ toxicity study. Kawashita H, Hiratsuka K, Kuroda J, Asada Y, Suzuki T, Muguruma Y, Tomioka S, Tani M, Kondo M, Mineshima H, Nagae Y.J Toxicol Sci. 2000 Oct;25 Spec No:51-62. PMID: 11349455
5:[Efficacy of combined chemoendocrine therapy with doxifluridine, cyclophosphamide, and fadrozole hydrochloride hydrate in a case of stage T4N3M1 breast cancer]. Ishida K, Fujii T, Takahashi T, Kawashima K, Hanaoka T, Mihara Y.Gan To Kagaku Ryoho. 2000 May;27(5):759-62. Japanese. PMID: 10832448
6:[Clinical trial of fadrozole hydrochloride for postmenopausal patients with recurrent breast cancer]. Kanzaki M, Nakaya Y, Kojima K, Toda H, Tobayama S, Machida H, Ohba M.Gan To Kagaku Ryoho. 1999 Jun;26(7):959-65. Japanese. PMID: 10396324
7:[A case of pleural and mediastinal lymph node metastases from breast cancer effectively treated with fadrozole hydrochloride in combination with cyclophosphamide]. Kokufu I, Kim YH, Peng YF, Fukuda K, Yamamoto M, Yano T, Yamada K, Kitano H.Gan To Kagaku Ryoho. 1999 Feb;26(3):377-9. Japanese. PMID: 10065105
8:Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma. Costa LA, Kopreski MS, Demers LM, Chinchilli VM, Santen RJ, Harvey HA, Lipton A.Cancer. 1999 Jan 1;85(1):100-3. PMID: 9921980
9:Fadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. Miller AA, Lipton A, Henderson IC, Navari R, Mulagha MT, Cooper J.Cancer. 1996 Aug 15;78(4):789-93. PMID: 8756373 Free Article
10:Studies on the effect of the new non-steroidal aromatase inhibitor fadrozole hydrochloride in an endometriosis model in rats. Yano S, Ikegami Y, Nakao K.Arzneimittelforschung. 1996 Feb;46(2):192-5. PMID: 8720312